Kura Oncology (KURA) Gross Margin (2025 - 2026)
Kura Oncology (KURA) reported Gross Margin of 98.57% for Q1 2026, down 143.0% year-over-year from 229.22% in Q1 2025, and down 1.43% quarter-over-quarter from 100.0% in Q1 2025.
Kura Oncology (KURA) Gross Margin (2025 - 2026) Analysis & Trends
Kura Oncology (KURA) has 2 years of Gross Margin data on file, last reported at 98.57% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 79.04% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Kura Oncology | 883.44 Mn | 883.44 Mn | 18.00 Mn | 98.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 98.57% |
| Mar 31, 2025 | 100.00% |